Immunome Statistics
Total Valuation
Immunome has a market cap or net worth of $602.95 million. The enterprise value is $344.94 million.
Important Dates
The last earnings date was Wednesday, November 13, 2024, after market close.
Earnings Date | Nov 13, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Immunome has 62.42 million shares outstanding. The number of shares has increased by 340.37% in one year.
Current Share Class | 62.42M |
Shares Outstanding | 62.42M |
Shares Change (YoY) | +340.37% |
Shares Change (QoQ) | +0.45% |
Owned by Insiders (%) | 4.12% |
Owned by Institutions (%) | 73.63% |
Float | 45.38M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 49.40 |
Forward PS | n/a |
PB Ratio | 2.62 |
P/TBV Ratio | 2.72 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 34.05 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.17, with a Debt / Equity ratio of 0.01.
Current Ratio | 6.17 |
Quick Ratio | 6.07 |
Debt / Equity | 0.01 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -276.36% and return on invested capital (ROIC) is -62.32%.
Return on Equity (ROE) | -276.36% |
Return on Assets (ROA) | -39.89% |
Return on Capital (ROIC) | -62.32% |
Revenue Per Employee | $184,164 |
Profits Per Employee | -$5.55M |
Employee Count | 55 |
Asset Turnover | 0.06 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +16.77% in the last 52 weeks. The beta is 1.82, so Immunome's price volatility has been higher than the market average.
Beta (5Y) | 1.82 |
52-Week Price Change | +16.77% |
50-Day Moving Average | 12.81 |
200-Day Moving Average | 16.05 |
Relative Strength Index (RSI) | 28.05 |
Average Volume (20 Days) | 755,980 |
Short Selling Information
The latest short interest is 10.47 million, so 16.77% of the outstanding shares have been sold short.
Short Interest | 10.47M |
Short Previous Month | 10.92M |
Short % of Shares Out | 16.77% |
Short % of Float | 23.07% |
Short Ratio (days to cover) | 18.28 |
Income Statement
In the last 12 months, Immunome had revenue of $10.13 million and -$305.35 million in losses. Loss per share was -$5.69.
Revenue | 10.13M |
Gross Profit | -81.00M |
Operating Income | -111.71M |
Pretax Income | -232.03M |
Net Income | -305.35M |
EBITDA | -110.44M |
EBIT | -111.71M |
Loss Per Share | -$5.69 |
Full Income Statement Balance Sheet
The company has $240.13 million in cash and $2.72 million in debt, giving a net cash position of $237.41 million or $3.80 per share.
Cash & Cash Equivalents | 240.13M |
Total Debt | 2.72M |
Net Cash | 237.41M |
Net Cash Per Share | $3.80 |
Equity (Book Value) | 214.91M |
Book Value Per Share | 3.56 |
Working Capital | 204.51M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$86.19 million and capital expenditures -$52.48 million, giving a free cash flow of -$138.68 million.
Operating Cash Flow | -86.19M |
Capital Expenditures | -52.48M |
Free Cash Flow | -138.68M |
FCF Per Share | -$2.22 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | -1,102.86% |
Pretax Margin | -3,014.59% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | -361.11% |
Dividends & Yields
Immunome does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -340.37% |
Shareholder Yield | -340.37% |
Earnings Yield | -52.29% |
FCF Yield | -23.75% |
Analyst Forecast
The average price target for Immunome is $28.60, which is 196.07% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $28.60 |
Price Target Difference | 196.07% |
Analyst Consensus | Strong Buy |
Analyst Count | 5 |
Revenue Growth Forecast (5Y) | 64.88% |
EPS Growth Forecast (5Y) | -53.89% |
Stock Forecasts Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Immunome has an Altman Z-Score of 8.55 and a Piotroski F-Score of 2.
Altman Z-Score | 8.55 |
Piotroski F-Score | 2 |